Semaglutide is marketed under three brand names to distinguish different indications and formulations: Ozempic (injectable for diabetes), Wegovy (injectable for obesity), and Rybelsus (oral for diabetes)
In another major analysis, researchers examined more than 30 million FDA adverse event reports to identify potential safety signals linked to GLP-1 drugs
doi: 10.3389/fendo.2025.1627909 Received 13 May 2025 Accepted 07 October 2025 Published 23 October 2025 Volume 16 - 2025 Edited by Francesc Xavier Guix, Ramon Llull University, Spain Reviewed by Anu Grover, Mangrove Creations LLP, India Adriyan Pramono, Diponegoro University, Indonesia Updates Copyright 2025 Ghobar, Tarhini, Osman, Sbeih, Ghayda, Matar, Haddad, Kanaan, Eid, Azar, Ghadieh and Harb
For athletes, biohackers, and anyone serious about optimizing recovery from injury, BPC-157 is worth understanding and (if appropriate for your situation) exploring